jwesth @jwesth: "𝙍𝙚𝙖𝙙𝙮 𝙛𝙤𝙧 𝙉𝙤𝙫𝙤 𝙉𝙤𝙧𝙙𝙞𝙨𝙠'𝙨 𝙌𝟮-𝙧𝙚𝙨𝙪𝙡𝙩𝙨? 🫄..."

United Kingdom

Edited

𝙍𝙚𝙖𝙙𝙮 𝙛𝙤𝙧 𝙉𝙤𝙫𝙤 𝙉𝙤𝙧𝙙𝙞𝙨𝙠'𝙨 𝙌𝟮-𝙧𝙚𝙨𝙪𝙡𝙩𝙨? 🫄 Tomorrow morning before market opening, we will get Q2-results from the Danish obesity (and diabetes) treatment giant $NOVO-B.CO (Novo Nordisk B A/S) . 💊 For Novo Nordisk , the second quarter results will be an important test of whether it can maintain the momentum behind sales of its obesity drug Wegovy and the diabetes drug Ozempic. These two blockbuster drugs are set to drive wild growth over the next few years. 📊 At the last quarterly presentation, Wegovy showed a slight weakness (at least compared to wild expectations), so I'll be watching closely to see if the obesity drug is back on the (fast) growth track. 🧑‍🔬 With three guidance upgrades in 2023, the bar is set high. So far, we've seen one 2024-outlook upgrade this year, with Novo's management expecting sales to grow 19-27% while increasing operating profit by 22-30%. 💪 With the huge growth expectations already factored into the company's valuation with a forward P/E at 35x, I think we may see disappointed investors if the result is 'just' as expected. But also, I would not be surprised if we once again see Novo follow the Danish 'Law of Jante' to underplay but overdeliver. $NVO (Novo-Nordisk A/S SPONS ADR) $LLY (Eli Lilly & Co) $SAN.PA (Sanofi) $SNY (Sanofi-ADR) $AMGN (Amgen Inc) $GMAB.CO (Genmab A/S) $GSK (GlaxoSmithKline plc ADR) $GSK.L (GlaxoSmithKline)

9 Mentioned Show all